Do you want the opportunity to contribute from initial ideas to clinical trials?

If you have experience in Drug Metabolism and Pharmacokinetics (DMPK) and want influence and impact opportunities far beyond the average, this is the role you have been looking for. As our new key DMPK specialist, you will define what needs to be done and when within your area of expertise – and you will do so from early drug discovery to clinical trials on both internal and partner projects.

Since this is a newly established position, you will have the opportunity to shape the role as well as our overall approach to DMPK. When joining Gubra, you can look forward to being part of a successful company that is truly a great place to work.

Key contributor in peptide projects across in vitro, ex vivo and in vivo experiments

Your primary focus will be internal peptide projects across a range of in vitro, ex vivo, and in vivo experiments, spanning from early drug discovery to First-in-Human (FIH) studies. This includes in vitro metabolism studies, dose setting, and PK/PD assessments, as well as FIH calculations – primarily within therapeutic areas focused on women’s health and metabolic and neurological diseases.

You will utilize your skills as part of dedicated project teams alongside specialist colleagues in computational drug discovery, peptide chemistry, molecular pharmacology, preformulation and in vivo pharmacology. You will also have close collaboration with laboratory technicians who are eager to continuously improve workflows.

Your primary tasks will include:

• Serving as the DMPK lead in drug discovery and development projects
• Applying PK/PD modeling and simulations to guide project decisions from early discovery to FIH studies
• Shaping and developing Gubra’s peptide DMPK workflows and processes
• Designing, developing, optimizing, and analyzing in vitro, ex vivo, and in vivo DMPK and PK/PD studies
• Communicating results and discussing new findings
• Collaborating with laboratory technicians to conduct LCMS-based bioanalysis

5+ years of DMPK experience and motivation to become our primary DMPK expert 

As an ambassador and torchbearer for a new area of expertise at Gubra, you must thrive on networking and constructive dialogue. You must also bring strong communication skills and perseverance to make DMPK a natural part of project design and general thinking across the organization.

In addition, collaboration must be a prominent part of your professional DNA – very little at Gubra happens without cross-functional teamwork. Finally, you will need an entrepreneurial mindset, including the ability to adapt to shifting priorities and the lack of fully defined templates and guidelines. You will help create these as we go.

Your background also includes:

• A natural science degree at the master’s level or higher
• 5+ years of DMPK experience 
• Hands-on LCMS experience
• The ability to design and analyze in vitro, ex vivo and in vivo DMPK studies
• Hands-on PK/PD modeling in R, Phoenix or similar

Your new team

You will join the bioanalysis team. We are currently three scientists and two laboratory technicians and part of the Drug Profiling department. We work in a welcoming environment built on trust, helpfulness, and a shared desire to break new ground. Naturally, we offer flexible working conditions, but in general we prefer to be together as much as possible, as it strengthens collaboration, accelerates innovation, and boosts team spirit. We are very much looking forward to welcoming you to the team.

Contact and application

Please apply at our website using the ”Apply” button. The deadline is December 14, 2025.

If you have any questions, you are very welcome to contact Senior Department Manager, Jakob Plum Christensen at jpc@gubra.dk. If necessary, we will set up an additional call to ensure your understanding of the job and your many opportunities.

We are looking forward to receiving your application. 

About Gubra 

Gubra is an ambitious contract research organisation (CRO) and biotech company striving for excellence at all levels. We insist on doing things efficiently – and often differently - to reach the results we aim for. Our vision is to become leaders in the fight for a more sustainable and healthier world. We do that by facilitating the discovery of new medicine, and by acting and inspiring others to fight the ongoing climate and biodiversity crises.  

Gubra’s activities are focused on the early stages of drug development and are organised in two highly synergistic business areas: CRO Services and Discovery & Partnerships (D&P). We generate our revenue by performing research for life science companies as well as by partnering projects from our discovery and development pipeline.  

Our therapeutic focus is within metabolic and fibrotic diseases, and we specialize in in vivo pharmacology, ex vivo assays, drug profiling, histology, stereology and whole brain and organ imaging. In addition, we offer a full palette of advanced transcriptomics. Our ML/AI-driven peptide drug discovery platform streaMLine enables us to rapidly develop a peptide hit into a non-clinical candidate ready for development. Through a constant focus on high quality, scientific excellence, speed, and solid teamwork we have established ourselves as a highly professional and competent partner in the market.  

People are our greatest asset, and our team consists of +270 employees all located in Hørsholm, Denmark. The mix of people from different cultures and educational backgrounds combined with our entrepreneurial mindset have greatly impacted our working environment, which is characterized by entrepreneurial drive, scientific curiosity, and teamwork – we join forces!